These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
595 related articles for article (PubMed ID: 21904379)
21. Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy. Ebinger M; Schwarze CP; Feuchtinger T; Scheel-Walter HG; Lang P; Hildenbrand S; Gessler P; Handgretinger R Pediatr Hematol Oncol; 2011 May; 28(4):334-7. PubMed ID: 21345080 [TBL] [Abstract][Full Text] [Related]
22. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Quezada G; Kopp L; Estey E; Wells RJ Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388 [TBL] [Abstract][Full Text] [Related]
23. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Sanz MA; Fenaux P; Lo Coco F; Haematologica; 2005 Sep; 90(9):1231-5. PubMed ID: 16154847 [TBL] [Abstract][Full Text] [Related]
24. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821 [TBL] [Abstract][Full Text] [Related]
25. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Breccia M; Lo-Coco F Expert Opin Pharmacother; 2012 May; 13(7):1031-43. PubMed ID: 22468778 [TBL] [Abstract][Full Text] [Related]
26. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639 [TBL] [Abstract][Full Text] [Related]
28. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334 [TBL] [Abstract][Full Text] [Related]
29. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies. Liu P; Han ZC Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848 [TBL] [Abstract][Full Text] [Related]
30. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Sahara N; Takeshita A; Satoh H; Terada H; Ohno R Leukemia; 2002 Apr; 16(4):617-22. PubMed ID: 11960341 [TBL] [Abstract][Full Text] [Related]
32. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Zhou J; Zhang Y; Li J; Li X; Hou J; Zhao Y; Liu X; Han X; Hu L; Wang S; Zhao Y; Zhang Y; Fan S; Lv C; Li L; Zhu L Blood; 2010 Mar; 115(9):1697-702. PubMed ID: 20029047 [TBL] [Abstract][Full Text] [Related]
33. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Iland HJ; Wei A; Seymour JF Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016 [TBL] [Abstract][Full Text] [Related]
34. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. Soignet SL; Maslak P; Wang ZG; Jhanwar S; Calleja E; Dardashti LJ; Corso D; DeBlasio A; Gabrilove J; Scheinberg DA; Pandolfi PP; Warrell RP N Engl J Med; 1998 Nov; 339(19):1341-8. PubMed ID: 9801394 [TBL] [Abstract][Full Text] [Related]
35. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474 [TBL] [Abstract][Full Text] [Related]
36. Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis. Ma H; Yang J Acta Haematol; 2015; 134(2):101-8. PubMed ID: 25925330 [TBL] [Abstract][Full Text] [Related]
37. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia. Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395 [TBL] [Abstract][Full Text] [Related]
38. Conventional induction and post-remission therapy in APL: have we arrived? Sanz MA; Iacoboni G; Montesinos P Best Pract Res Clin Haematol; 2014 Mar; 27(1):33-8. PubMed ID: 24907015 [TBL] [Abstract][Full Text] [Related]
39. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. Mathews V; George B; Chendamarai E; Lakshmi KM; Desire S; Balasubramanian P; Viswabandya A; Thirugnanam R; Abraham A; Shaji RV; Srivastava A; Chandy M J Clin Oncol; 2010 Aug; 28(24):3866-71. PubMed ID: 20644086 [TBL] [Abstract][Full Text] [Related]
40. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Soignet SL; Frankel SR; Douer D; Tallman MS; Kantarjian H; Calleja E; Stone RM; Kalaycio M; Scheinberg DA; Steinherz P; Sievers EL; Coutré S; Dahlberg S; Ellison R; Warrell RP J Clin Oncol; 2001 Sep; 19(18):3852-60. PubMed ID: 11559723 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]